Metraipolis › archive › dc_2923e89910cc

Tezepelumab in real-world US patients with severe asthma across phenotypes and underrepresented populations: the phase 4 PASSAGE study — Europe PMC PMID:42148905

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42148905
DOI
10.1093/ajrccm/aamag225
License (as archived)
solo-consultazione
Archived
2026-10-16T13:03:46.456Z
SHA-256 of the archived text
a7188a165d6eb8e1eaa0483ffc4accd9c9fc6253fe3650f3219e21e2c6304bd0
Stable URL of this page
https://metraipolis.com/documento/dc_2923e89910cc

How to cite

Tezepelumab in real-world US patients with severe asthma across phenotypes and underrepresented populations: the phase 4 PASSAGE study — Europe PMC PMID:42148905 — Europe PMC (en), https://europepmc.org/article/MED/42148905 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2923e89910cc (Metraipolis archive dc_2923e89910cc, sha256 a7188a165d6eb8e1eaa0483ffc4accd9c9fc6253fe3650f3219e21e2c6304bd0)
BibTeX
@misc{dc2923e89910cc,
  title = {Tezepelumab in real-world US patients with severe asthma across phenotypes and underrepresented populations: the phase 4 PASSAGE study — Europe PMC PMID:42148905},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42148905},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2923e89910cc; sha256 a7188a165d6eb8e1eaa0483ffc4accd9c9fc6253fe3650f3219e21e2c6304bd0},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42148905. Agents can read the archived copy with the MCP tool read_document.